This test looks for autoantibodies that target ganglionic nicotinic acetylcholine receptors (α3-AChR)—key “signal docks” inside the autonomic nervous system, which controls involuntary functions like blood pressure, heart rate, sweating, digestion, and bladder function.
If your immune system makes these antibodies, it can disrupt autonomic signaling and cause dysautonomia. The most specific condition is Autoimmune Autonomic Ganglionopathy (AAG).
Why Doctors Order It
Your clinician may order this test if you have unexplained autonomic symptoms, such as:
-
Orthostatic hypotension (lightheadedness or fainting when standing)
-
Dry mouth / dry eyes
-
Abnormal sweating (too much or too little)
-
Digestive issues (constipation, nausea, bloating, early fullness)
-
Bladder problems (retention, urgency, incontinence)
-
Pupil abnormalities (light sensitivity, blurry vision)
-
Erectile dysfunction or heart-rate/blood-pressure instability
It’s also used when clinicians suspect paraneoplastic (cancer-related) neurologic disease—most often with small cell lung cancer or thymoma.
Typical Reference Range
Ranges vary by lab. Common interpretations:
-
Negative: < 0.02 nmol/L
-
Borderline / Indeterminate: 0.02–0.05 nmol/L
-
Positive: > 0.05 nmol/L
-
High positive (often more specific for AAG): > 0.20 nmol/L
Always interpret your exact value using the reference interval on your report.
Understanding Your Results
If Your Result is Elevated / Positive
What it suggests:
-
Supports an autoimmune cause of dysautonomia, most notably AAG.
-
Higher titers often track with more severe or widespread autonomic involvement, though exceptions exist.
What to do next:
-
Share the result with your clinician. They may recommend:
-
Autonomic function testing (tilt-table, QSART/sweat testing, heart-rate variability)
-
Targeted cancer screening (e.g., CT chest, PET/CT, or other imaging) to rule out paraneoplastic causes
-
Expanded autoantibody panels (paraneoplastic/neuronal antibodies)
-
-
Discuss immunotherapy options where appropriate: IVIG, plasma exchange, corticosteroids, or steroid-sparing agents (e.g., rituximab, mycophenolate, azathioprine).
-
Symptom-focused care for blood pressure, GI motility, bladder function, and temperature/sweating can improve daily life.
Practical tips while you wait for care:
-
For orthostatic symptoms: rise slowly, hydrate well, consider compression stockings, and ask about salt/fluid strategies if safe for you.
-
Track blood pressure and symptom patterns to share with your clinician.
If Your Result is Borderline / Indeterminate
What it suggests:
-
Low-level positivity can occur with limited or early disease, other autoimmune conditions, or occasionally without clear disease.
What to do next:
-
Correlate with symptoms and autonomic testing.
-
Your clinician may repeat the test or add related antibody panels.
-
Continue evaluation for common non-autoimmune causes of similar symptoms (medications, dehydration, diabetes, Parkinsonian syndromes, etc.).
If Your Result is Negative
What it suggests:
-
Makes antibody-mediated AAG less likely, but does not fully exclude it. A minority of patients can be seronegative.
-
Think broadly: medication side effects, volume depletion, neuropathies (e.g., diabetes), POTS, neurodegenerative conditions.
What to do next:
-
If symptoms persist or are severe, ask about autonomic function testing, alternative antibodies, and evaluation for other causes of dysautonomia.
Related / Reflex Tests
-
Autonomic reflex screen (tilt-table, QSART, heart-rate variability to deep breathing/Valsalva)
-
Paraneoplastic antibody panel (e.g., anti-Hu/ANNA-1, CRMP-5, etc.)
-
Cancer screening when clinically indicated (CT chest, PET/CT, mammography, colonoscopy, based on age/risk)
-
Basic labs to rule out mimics: CBC, CMP, fasting glucose/HbA1c, B12, TSH, SPEP, autoimmune panels
Conditions Linked to Positive Ganglionic AChRAb
-
Autoimmune Autonomic Ganglionopathy (AAG)
-
Paraneoplastic autonomic neuropathy (notably small cell lung carcinoma)
-
Thymoma-associated autoimmunity
-
Occasionally seen with other systemic autoimmune diseases
Treatment & Outlook
-
Many patients benefit from immunotherapy (IVIG, plasma exchange, corticosteroids; selected cases: rituximab or other immunosuppressants).
-
Symptom-targeted therapies (midodrine, droxidopa, fludrocortisone for orthostatic hypotension; pro-motility agents for GI symptoms; bladder protocols) improve quality of life.
-
Monitoring titers over time can help some clinicians track disease activity, but symptom changes and autonomic testing usually guide treatment decisions.
-
Some patients recover partially or fully; others may have a chronic or relapsing course.
FAQs
Is a high titer always severe disease?
No. Higher levels often correlate with severity, but not perfectly. Clinical evaluation remains essential.
Can I have AAG with a negative test?
Yes—seronegative AAG exists. Diagnosis relies on symptoms + autonomic testing, not the antibody alone.
Should everyone with a positive test get cancer screening?
Your clinician will tailor screening to your age, risks, and symptoms, but a thoughtful search is common with positive results, especially at higher titers.
How fast do treatments work?
Response varies by therapy and disease severity. Some patients notice improvement within weeks, others months. Ongoing follow-up is important.
How to Use Your Result
-
Match the number to your lab’s reference range.
-
Document your symptoms (when they start, what triggers/worsens them).
-
Share the result with your healthcare provider and discuss next steps (testing, screening, treatment).
-
Track progress: blood pressure logs, hydration, and symptom diaries can guide care.
Safety Note
Seek urgent care for fainting with injury, chest pain, severe dehydration, or sudden neurologic changes.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.